Opthea Limited - ADR
OPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$524.37M
Close$
$0.22
93.4% downside
Current Fair Value
93.4% downsideOvervalued by 93.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $524.37 Million |
|---|---|
| Enterprise Value | $502.24 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $-1.04 |
| Beta | 1.67 |
| Outstanding Shares | 153,774,846 |
Return
| Return on Equity | 236.09% |
|---|---|
| Return on Assets | 223.99% |
| Return on Invested Capital | -1456.51% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5590.75 |
| Enterprise Value to EBIT | -1.53 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1,100
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Opthea Limited
33 employees
CEO: Megan Baldwin Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D...